Trial Profile
A Single Center, Open-label Study to Evaluate the Effects of a Single 1200mg IV Dose of Oritavancin on the Results of Multiple Coagulation Tests in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Dec 2023
Price :
$35
*
At a glance
- Drugs Oritavancin (Primary)
- Indications Bacteraemia; Skin and soft tissue infections
- Focus Pharmacodynamics
- Sponsors Melinta Therapeutics; The Medicines Company
- 12 Dec 2016 Results published in the Antimicrobial Agents and Chemotherapy.
- 30 Oct 2016 Results assessing interference of Oritavancin on coagulation tests presented at the IDWeek 2016.
- 16 Mar 2015 Status changed from recruiting to completed as per ClinicalTrials.gov reocrd.